Abstract
Objective To investigate the differences of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia (CAP).Methods A analysis of 140 cases of CAP patients,were randomly divided into two groups,of which 70 cases piperacillin sulbactam sodium; remaining 70 cases moxifloxacin comparative clinical efficacy.Results The moxifloxacin group therapy effective rate of 88.57％ greater than 68.57％ of the piperacillin,the differences were statistically significant(P＜0.05).Conclusions Moxifloxacin in the treatment of CAP more effective than piperacillin sulbactam sodium,and the appropriate cost worth in clinical practice,patients Adaptation and contraindications. Key words: piperacillin sulbactam sodium; moxifloxacin; CAP
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
